CGEM Stock Overview
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Cullinan Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.15 |
| 52 Week High | US$15.89 |
| 52 Week Low | US$7.30 |
| Beta | 0.0065 |
| 1 Month Change | 10.18% |
| 3 Month Change | -18.14% |
| 1 Year Change | -13.16% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.72% |
Recent News & Updates
Shareholder Returns
| CGEM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.8% | 0.7% | 2.3% |
| 1Y | -13.2% | 7.1% | -9.7% |
Return vs Industry: CGEM underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: CGEM underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| CGEM volatility | |
|---|---|
| CGEM Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CGEM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CGEM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Nadim Ahmed | https://www.cullinanoncology.com |
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company’s lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein.
Cullinan Oncology, Inc. Fundamentals Summary
| CGEM fundamental statistics | |
|---|---|
| Market Cap | US$438.47m |
| Earnings (TTM) | US$105.48m |
| Revenue (TTM) | n/a |
4.2x
P/E Ratio0.0x
P/S RatioIs CGEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGEM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$105.48m |
| Earnings | US$105.48m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CGEM perform over the long term?
See historical performance and comparison